EloraTZP
Code LY900043
Lilly pairs its amylin analog eloralintide with tirzepatide. Phase 2 in type 2 diabetes gave 23.3 percent weight loss at the top combination; two AMPLIFY phase 3 trials were registered in October 2026.
EloraTZP comes from Eli Lilly and sits in the Amylin class on the board. Route: weekly injection. Use tracked here: Obesity with or without type 2 diabetes. It stands at Phase 3 on the board, with 1 news move logged; the latest is dated 26 Oct 2026.
- 05ApprovedCleared for sale in at least one major market for this use.
- 04FiledApplication submitted to a regulator and under review.
- 03Phase 3Here now
- 02Phase 2Does it work at all, and at which dose? Hundreds of patients.
- 01Phase 1First doses in people. Safety, dose range, how the body handles it.
- Company
- Eli Lilly
- Mechanism
- Combination of eloralintide, an amylin receptor agonist, with tirzepatide, a GIP and GLP-1 receptor agonist
- Given as
- weekly injection
- Lead use on the board
- Obesity with or without type 2 diabetes
- Moves logged
- 1latest 7 days ago
EloraTZP news moves
-
EloraTZP phase 3 trials registered as Lilly pairs an amylin analog with tirzepatide
Two AMPLIFY trials with 3,115 planned participants will test eloralintide plus tirzepatide for 100 weeks. Phase 2 showed more weight loss than tirzepatide alone, and more people stopping for side effects.
Other amylin molecules on the board, with their current stage.